Purpose: Breast cancer-related lymphedema (BCRL) is a chronic, progressive side effect of breast cancer treatment, occurring in one-third of patients treated with axillary lymph node dissection and nodal radiotherapy. Cluster of differentiation 4-positive (CD4) cells plays a key role in BCRL by facilitating inflammation and inhibiting lymphangiogenesis. Tacrolimus is an anti-inflammatory and immunosuppressive macrolide that targets CD4 cells. Treatment of lymphedema with topical tacrolimus has revealed promising results in preclinical trials. This clinical trial was aimed at evaluating the feasibility, safety, and effect of tacrolimus in women with stage I or II BCRL, according to the International Society of Lymphology.
Methods: We conducted this open-label, single-arm, phase II pilot trial from September 2020 to April 2021. Eighteen women with BCRL stage I or II BCRL were treated with topical tacrolimus for 6 months and followed up at 3 and 6 months. The primary outcome was arm volume, and secondary outcomes were the lymphedema index (L-Dex), health-related quality of life (HRQoL), lymph flow and function, and safety and feasibility of the trial design.
Results: The mean lymphedema arm volume and L-Dex reduced significantly by 130.44 ± 210.13 mL ( < 0.05; relative reduction: 3.6%) and 3.54 ± 4.98 ( < 0.05), respectively, and health-related quality of life scores was improved significantly ( < 0.05). According to the MD Anderson scale, in terms of lymph flow and function, three patients (16.7%) showed improvement, while none showed worsening. Lymph flow or function showed no change according to the Arm Dermal Backflow scale.
Conclusion: In this trial, treatment with tacrolimus was safe and feasible in women with stage I or II BCRL. Tacrolimus alleviated BCRL in terms of improved arm volume, L-Dex, and HRQoL. Assessments of lymph flow and function were positive, although inconclusive. Larger randomized controlled trials are required to verify these findings.
Trial Registration: ClinicalTrials.gov Identifier: NCT04541290.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981991 | PMC |
| http://dx.doi.org/10.4048/jbc.2023.26.e2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The necroptosis-related lncRNA ENSG00000253385.1 promotes the progression of esophageal squamous cell carcinoma by targeting the miR-16-2-3p/VDAC1 axis.
Sci Rep
January 2025
Emergency department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Esophageal squamous cell carcinoma (ESCC) is one of the most common digestive malignancies. Our previous studies revealed necroptosis-related lncRNA ENSG00000253385.1 was an independent prognostic factor for ESCC.
View Article and Find Full Text PDFEBUS-TBNA and CryoEBUS of the mediastinal lymph node. One hundred seventy-eight cases. Validation of the WHO Reporting System for Lymph Node Cytopathology. Proposed CryoEBUS diagnostic flow chart and indications. The view of the interventional pathologist.
Rev Esp Patol
January 2025
Hospital Universitario Central de Asturias, Pathology Department, Universidad de Oviedo, Oviedo, Spain. Electronic address:
Introduction: Microscopic assessment is essential in the study of mediastinal lymph nodes. Obtaining cytological samples through Endobronchial Ultrasound TransBronchial Needle Aspiration (EBUS-TBNA) has long been considered the gold standard procedure. The implementation of the World Health Organization (WHO) Reporting System for Lymph Node Cytopathology, along with the advancement of the CryoEBUS lymph node technique, has enhanced and refined diagnostic accuracy in this field.
View Article and Find Full Text PDFMaternal milk cell components are uptaken by infant liver macrophages via extracellular vesicle mediated transport.
FASEB J
January 2025
Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA.
Milk is a multifaceted biofluid that is essential for infant nutrition and development, yet its cellular and bioactive components, particularly maternal milk cells, remain understudied. Early research on milk cells indicated that they cross the infant's intestinal barrier and accumulate within systemic organs. However, due to the absence of modern analytical techniques, these studies were limited in scope and mechanistic analysis.
View Article and Find Full Text PDFAn Unusual Case of Chylous Ascites.
Cureus
December 2024
Hepatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Chylous ascites occur when the lymphatic flow is blocked or disrupted, causing a leakage of fluid into the peritoneal space. It can be caused by a number of etiologies and identifying the exact cause can be challenging. We present the case of a 77-year-old man who presented with chylous ascites.
View Article and Find Full Text PDFDual-modal radiomics ultrasound model to diagnose cervical lymph node metastases of differentiated thyroid carcinoma: a two-center study.
Cancer Imaging
January 2025
Department of Ultrasound, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine of Chinese Academy of Medical Sciences, Beijing, China.
Objectives: To establish and validate a dual-modal radiomics nomogram from grayscale ultrasound and color doppler flow imaging (CDFI) of cervical lymph nodes (LNs), aiming to improve the diagnostic accuracy of metastatic LNs in differentiated thyroid carcinoma (DTC).
Methods: DTC patients with suspected cervical LNs in two medical centers were retrospectively enrolled. Pathological results were set as gold standard.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!